Opendata, web and dolomites

FIDELIO SIGNED

Training network for research into bone Fragility In Diabetes in Europe – towards a personaLised medIcine apprOach

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 FIDELIO project word cloud

Explore the words cloud of the FIDELIO project. It provides you a very rough idea of what is the project "FIDELIO" about.

develops    imposes    hormones    techniques    biologists    genetic    worldwide    aging    mostly    esrs    epidemic    geneticists    bmd    lack    experts    unknown    fractures    preclinical    biological    professional    fidelio    mortality    relative    largely    area    quality    webinars    epidemiologists    mellitus    despite    burden    unravelling    date    individual    offers    employ    interdisciplinary    bone    normal    markers    cutting    stage    companies    clinicians    courses    succeed    mechanisms    suggests    altered    technologies    training    morbidity    entrepreneurial    risk    density    patient    stratification    emerged    skills    collaborative    treatment    osteoporosis    multidisciplinary    society    models    databases    artificial    transferable    broad    trained    vitro    subsequent    derive    individualized    cohorts    diabetes    disease    entrepreneurs    interventions    anabolic    imaging    joint    supporting    fold    fracture    healthcare    diabetic    fragility    secondments    intelligence    edge    environment    predictive    residential    mineral    engineers    form   

Project "FIDELIO" data sheet

The following table provides information about the project.

Coordinator
TECHNISCHE UNIVERSITAET DRESDEN 

Organization address
address: HELMHOLTZSTRASSE 10
city: DRESDEN
postcode: 1069
website: http://www.tu-dresden.de/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 3˙810˙146 €
 EC max contribution 3˙810˙146 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2019
 Funding Scheme MSCA-ITN-ETN
 Starting year 2019
 Duration (year-month-day) from 2019-10-01   to  2023-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TECHNISCHE UNIVERSITAET DRESDEN DE (DRESDEN) coordinator 505˙576.00
2    SYDDANSK UNIVERSITET DK (ODENSE M) participant 595˙044.00
3    EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH CH (ZUERICH) participant 562˙553.00
4    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) participant 531˙239.00
5    UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF DE (HAMBURG) participant 505˙576.00
6    THE UNIVERSITY OF SHEFFIELD UK (SHEFFIELD) participant 303˙172.00
7    UNIVERSITE DE GENEVE CH (GENEVE) participant 281˙276.00
8    TAMIRNA GMBH AT (WIEN) participant 264˙207.00
9    UNIVERSITA CAMPUS BIO MEDICO DI ROMA IT (ROMA) participant 261˙499.00

Map

 Project objective

Diabetes mellitus has emerged as a novel risk factor for fragility fractures. While in type 1 diabetes the 3-fold overall relative risk for fractures may mostly derive from low bone mineral density (BMD) likely due to the lack of the bone-anabolic hormones, in type 2 diabetes, the fracture risk is increased about 2-fold, despite a normal or even higher BMD. This suggests that bone fragility in each form of diabetes develops by distinct mechanisms that to date remain largely unknown and may require an individualized approach for effective treatment. As the diabetes epidemic is increasing worldwide with aging, and the fractures that are associated with diabetes cause an increase in morbidity, mortality, and healthcare costs, diabetes-induced osteoporosis imposes a significant burden on our society and our healthcare system.

FIDELIO offers a comprehensive, multidisciplinary training program for Early Stage Researchers (ESRs) in this emerging field, unravelling i) the biological mechanisms that contribute to altered bone quality parameters with subsequent bone fragility in diabetes, ii) identify predictive markers for patient stratification and individualized interventions, and iii) develop novel imaging techniques to determine bone quality aspects. The research will employ well-defined patient cohorts, preclinical models of diabetic bone disease, in vitro studies, genetic databases, artificial intelligence, and cutting-edge imaging technologies in a highly collaborative and interdisciplinary environment. ESRs will be trained through individual research projects, secondments, residential courses, and webinars provided by a broad range of experts, including bone biologists, clinicians, epidemiologists, geneticists, engineers and entrepreneurs, as well as companies supporting this important area of research. The joint training programme will also develop transferable and entrepreneurial skills to help the ESRs succeed in their choice of professional future.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FIDELIO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FIDELIO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

SAMCAPS (2018)

Self-Assembled MicroCAPSules: Synthesis, Characterization, and Eco-friendly Application in Home Care Products

Read More  

NU-SPINE (2019)

Training innovative future leaders in research and development of materials and implants for the spine

Read More  

INSPIRE (2020)

INnovation in Safety Pharmacology for Integrated cardiovascular safety assessment to REduce adverse events and late stage drug attrition.

Read More